4//SEC Filing
BAY CITY CAPITAL LLC 4
Accession 0001104659-21-130027
CIK 0001840233other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 5:02 PM ET
Size
15.1 KB
Accession
0001104659-21-130027
Insider Transaction Report
Form 4
BAY CITY CAPITAL LLC
10% Owner
Transactions
- Conversion
Common Stock
2021-10-26+665,696→ 665,696 total(indirect: See footnotes) - Conversion
Series B Preferred Stock
2021-10-26−6,324,110→ 0 total(indirect: See footnotes)→ Common Stock (665,696 underlying) - Conversion
Common Stock
2021-10-26+151,294→ 816,990 total(indirect: See footnotes) - Conversion
Series C Preferred Stock
2021-10-26−1,437,297→ 0 total(indirect: See footnotes)→ Common Stock (151,294 underlying) - Purchase
Common Stock
2021-10-26$16.00/sh+312,500$5,000,000→ 1,129,490 total(indirect: See footnotes)
Footnotes (4)
- [F1]The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
- [F2]The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
- [F3]Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co.
- [F4]Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001288452
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 5:02 PM ET
- Size
- 15.1 KB